Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 16Recruiting 13Completed 8Withdrawn 4Terminated 4Unknown 2Not yet recruiting 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Genitourinary 3Tumor-Agnostic 2Lymphoid 2Gastrointestinal 2CNS 2Thoracic 1Sarcoma 1Myeloid 1Gynecologic 1Classical hematology 1Breast 1

Conditions

Osteosarcoma 1Neuroblastoma 1

Interventions

Specimen Handling 3trastuzumab deruxtecan 1tivozanib 1pembrolizumab 1pegamotecan 1fludarabine phosphate 1envafolimab 1cemiplimab 1atezolizumab 1apatinib 1aldesleukin 1X-Rays 1Vincristine 1Vaccines 1Temozolomide 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Nanoparticles 1Magnetic Resonance Spectroscopy 1Health Care Economics and Organizations 1HMPL-013 1Everolimus 1Cyclophosphamide 1Biopsy 1Biomarkers 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Biopsy × Sarcoma × Clear all
NCT04539366 2026-05-13

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

National Cancer Institute (NCI)

Phase 1 Suspended
67 enrolled
CNSSarcoma

Neuroblastoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡